Backed by NEA and Norwest.
About the role
If you’re passionate about advancing innovative treatments for patients and shaping the future of precision peptide therapeutics, this is your chance to make a real impact alongside a fast-paced, growing, mission-driven team. To learn more, visit our website mbxbio.com and follow us on LinkedIn .
What they're looking for
- Manage CROs and contractors to ensure compliance, high-quality deliverables, adherence to timelines, and budget alignment
- Maintain and enhance the internal SAS macro library and database
- Provide statistical programming input for SAPs, publications, scientific presentations, regulatory submissions, and promotional materials
- Review Case Report Forms (CRFs), CRF annotations, SAPs, Table, Listing, and Figure (TLF) shells, TLF outputs, dataset specifications (SDTM and ADaM)
- Serve as a lead for statistical programming within study teams, effectively communicating statistical and programming issues to development teams
- Contribute to the development of programming standards, macros, SOPs, and process improvements within the Biometrics function
More about this role
Working with Us
MBX Biosciences is a clinical-stage biopharmaceutical company headquartered in Carmel, Indiana, with a secondary office in Burlington, MA. Our mission is to transform the lives of people impacted by endocrine and metabolic disorders through our novel precision peptides.
Leveraging our proprietary Precision Endocrine Peptides (PEPs)™ platform, we are pioneering technology designed to overcome key limitations of existing therapies and enhance efficacy, tolerability, safety and convenience. Our team is advancing a pipeline of novel candidates with clinically validated targets, established endpoints for regulatory approval, and strong market potential.
Our pipeline includes canvuparatide (MBX 2109) for the treatment of chronic hypoparathyroidism, currently preparing for Phase 3 development, and a growing obesity portfolio that includes MBX 4291 in Phase 1 development, MBX 5765, a next-generation amycretin prodrug designed for once-monthly dosing, as well as MBX 6180, a GLP/GIP/GCGR triple agonist prodrug for once monthly dosing; all of which optimize our PEP platform.
If you’re passionate about advancing innovative treatments for patients and shaping the future of...
Browse similar: Startup jobs